Wellington Management Group LLP Boosts Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Wellington Management Group LLP grew its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 56.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,016 shares of the medical research company's stock after acquiring an additional 3,601 shares during the period. Wellington Management Group LLP's holdings in Bio-Rad Laboratories were worth $3,351,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of BIO. Van ECK Associates Corp grew its holdings in Bio-Rad Laboratories by 97.8% during the 3rd quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company's stock worth $436,861,000 after acquiring an additional 644,530 shares in the last quarter. Select Equity Group L.P. boosted its stake in shares of Bio-Rad Laboratories by 26.2% during the second quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company's stock valued at $177,391,000 after purchasing an additional 134,856 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company's stock valued at $173,773,000 after buying an additional 634,311 shares during the period. Earnest Partners LLC lifted its holdings in Bio-Rad Laboratories by 17.8% during the second quarter. Earnest Partners LLC now owns 606,788 shares of the medical research company's stock worth $165,720,000 after buying an additional 91,882 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Bio-Rad Laboratories by 64.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company's stock valued at $135,081,000 after acquiring an additional 193,700 shares in the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO traded down $13.91 on Wednesday, hitting $323.94. 171,899 shares of the company were exchanged, compared to its average volume of 241,148. The firm has a market capitalization of $9.07 billion, a P/E ratio of -11.85 and a beta of 0.90. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 1-year low of $262.12 and a 1-year high of $387.99. The stock's 50 day moving average price is $341.06 and its 200 day moving average price is $322.09.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The business had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. During the same period in the prior year, the company earned $2.33 earnings per share. The company's revenue was up 2.8% on a year-over-year basis. Sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current year.

Wall Street Analyst Weigh In

BIO has been the subject of several recent research reports. Royal Bank of Canada boosted their price target on Bio-Rad Laboratories from $369.00 to $481.00 and gave the stock an "outperform" rating in a research report on Monday, December 9th. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target on the stock. StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Finally, Citigroup raised their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $394.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.